Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer…

Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful reversal rocketing back into penny land on Friday up 46% on $1.6 million in dollar volume. RGBP has a massive following of shareholders, many of them international that are jumping on board and accumulating heavily now that RGBP has reversed. Several weeks ago, the Company announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine. RGBP CEO Dr. David Koos stated: We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.

Microcapdaily has been reporting on RGBP since early last year. The last time we covered the Company we stated among other things: RGBP is one of the most followed stocks in small caps with a huge investors base and it has a long history of big moves skyrocketing to 8 cents plus twice over the past 12 months. There are also plenty of buyout rumors on RGBP; notably in the July PR Dr. koos stated: We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. Rumors are circulating that Dr. Koos has offers for either a B/O or potential joint ventures, licensing, partnerships, or a merger. He wants to get the best offer out there. Regen owns a valuable intellectual property portfolio including 8 issued patents and 13 published patent applications, these patents address enormous billion-dollar markets. RGBP has not seen the kind of volume and interest it showed on Friday in a long time and looks to be preparing to embark on something substantial here.

Regen BioPharma Inc (OTCMKTS: RGBP) is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.

Regen owns a valuable intelectuable property portfolio including 8 issued patents and 13 published patent applications. Zander Therapeutics, Inc. (a company under common control) has been granted an exclusive license to develop and commercialize IP controlled by the Company for non-human veterinary therapeutic use. Regen has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize Antigen specific mRNA cellular cancer vaccines for the treatment of pancreatic cancer and KCL Therapeutics, Inc. has granted an exclusive license to Oncology Pharma, Inc. to develop and commercialize certain intellectual property for the treatment of colon cancer.

The Company is led by CEO David Koos who has over 30 years of investment banking and venture capital experience. He has a deep knowledge of startup businesses, public markers and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. Dr. Koos has a Ph.D. in Sociology and a Doctor of Business Administration with an emphasis in finance. Additionally, he has authored / co-authored numerous peer reviewed journal articles. Dr. Koos worked hard to get the filings up to date and get the Company compliant which has recently been completed with RGBP now pink current

Earlier this year RGBP announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regens existing siRNA (small interfering RNA) intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. mRNA is a single-stranded molecule that carries genetic code from DNA in a cells nucleus to ribosomes (the cells protein-making machinery).

Regen has filed an Investigational New Drug Application (IND#16928) for their drug termed tCellVax with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. Dyo Biotechnologies has been contracted to assist Regen with the development of the above-mentioned technology.

To Find out the inside Scoop on RGBPSubscribe to Microcapdaily.com Right Now by entering your Email in the box below

$RGBP We're all agree the worst is already behind us The chart is so ready for a blowout run with any major news Until then we'll take a nice n steady organic upwards MrKoos should throw us a prime ribs anydays now??

— CHUONG PHAN (@CHUONGPHAN1974) August 4, 2022

On July 26 RGBP announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.

In 2021 the Company was granted US patent # 11,090,332 on composition of matter of survivin modified-mRNA useful for teaching the immune system to kill cancer. In the current patent, specific types of dendritic cells, means of generating specialized dendritic cells, and the planned formulation that will enter clinical trials have been granted patent protection.

Immunotherapy of cancer represents a very large market which is currently being led by the class of drugs called checkpoint inhibitors and CAR-T cells. To date there is no mRNA immunotherapy available for treating cancer. This patent application protects the use of our patented survivin mRNA both as a stand-alone vaccine and as an immunotherapy.

RGBP CEO Dr. David Koos stated: We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.

$RGBP has been on fire lately ?

Up 42% on Friday with lots of buys 30 min before closing bell.

Dollar Volume Friday: $1.4 million ?

Keeps moving up further with HEAVY accumulation of shares building since Wednesday 8/3 ?#OTC #OTCMARKETS #OTCUNITED #Pennystocks pic.twitter.com/NNoZ1zo1pS

— Pennies2Riches ? (@GeniusTrader777) August 6, 2022

For more on RGBP Subscribe Right Now!

Currently trading at a $55 million market valuation RGBP has 5,024,517,324 shares outstanding and a debt load that has caused significant dilution in the past. But RGBP is an exciting story developing in small caps, at current levels the selling pressure that decimated the share price from over $0.08 to half a penny is gone and buyers have stepped in and are accumulating heavily at current levels. RGBP is no stranger to big moves and has runner in its blood skyrocketing to $0.0819 not once but twice in the past year alone. Several weeks ago, the Company announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine. RGBP CEO Dr. David Koos stated: We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine. Rumors are circulating that Dr. Koos has offers for either a B/O or potential joint ventures, licensing, partnerships, or a merger. He wants to get the best offer out there. Regen owns a valuable intellectual property portfolio including 8 issued patents and 13 published patent applications, these patents address enormous billion-dollar markets. RGBP has not seen the kind of volume and interest it showed on Friday in a long time and looks to be preparing to embark on something substantial here. We will be updating on RGBP when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with RGBP.

Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article

See the original post:
Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer...

Man gets life-saving treatment close to home – INFORUM

FARGO On Wednesday, June 15, Ron Beck received an infusion to help with bone-hardening. It's a crucial step to bounce back after numerous chemotherapy treatments for his multiple myeloma, a cancer that affects the blood, bones, and bone marrow.

"With the liquid chemo that they gave me the first day in the hospital, that wiped out my immune system. And everything else. So we're building my body back a little at a time," said Beck as we sat in on his infusion session.

The 69 year-old Menagha man spent 42 years in banking before he got into pastoral work. That he said, has helped him stay positive after his initial diagnosis in June of 2021.

"She said, 'Well, you're not responding like most cancer patients would respond,' and I said, 'I've got the Lord, I don't have to worry about what's going to happen,'" Beck recalled.

After he started treatments at a smaller cancer center, they switched to Roger Maris, just 90 miles away from his home.

"I would not have gone to the Mayo or the university at my age. I would have probably said, 'Hey, let's just do whatever we can do,' and whatnot, because I don't want to be that far away and go through it," he said.

Beck became just the fourth person to get a stem cell, or bone marrow, transplant since Roger Maris added the treatment in 2021.

Doctors say it's a chance to get back to a normal life.

"With all these sacrifices up front, getting people to a position where they can enjoy attending church and enjoy playing golf, and enjoy being around family with kind of minimal toxicity, that's kind of the overarching goal of what we do," said Dr. Seth Maliske, a doctor of hematology and stem cell transplants at Roger Maris Cancer Center, as well as Beck's doctor.

Beck says it was the staff and Maliske's treatment that made him feel at home during the challenging days.

"They treated you like family. They treated you all the way around; they just brought you in and took care of you. And I mean, it was like you're the only patient they have," he said.

See the rest here:
Man gets life-saving treatment close to home - INFORUM

CHILDREN WITH AUTISM: SPECIAL, BUT JUST ONE OF US – The Hindu

Autism is a disorder of brain development, where the child has difficulty in social interaction and communication. Each child with autism is different and presents slightly differently.

Since speech is one of the most important forms of communication, these children often have delayed speech and language. This must never be ignored or passed off casually.Aware and alert parents may notice impaired speech development in children less than even 2 years of age and get the child assessed early.

Many children may able to repeat things like alphabets or full rhymes which they have heard, instead of speaking to communicate or interact with people around, and this may be mistaken for normal speech development. However, they have poor eye contact, may not respond to their name when called, may not wave bye bye, or play with other children in an interactive way. This does not mean that they have no feelings, or love and affection; they can be very attached to caregivers and siblings, and may just show it in different ways.

Children with autism may also have associated difficulties in chewing food, constipation, sleep disturbances. They may have certain repetitive behaviours. They may often be hyperactive and have behaviour issues like temper tantrums.

Occasionally, some of the children have very advanced skills and abilities eg music, maths, spelling, reading or writing. They are said to have a savant ability.

What causes autism is as yet unknown, but genetic factors are most likely involved. Increased use of screens in young children less than 2 years of age may result in features of autism, in children who are predisposed to this developing this condition. During Covid times and in the subsequent period, there has been a marked increase in number of cases of autism, because the children were isolated socially.

There is no cure, but the early diagnosis and appropriate therapy are important for best results.

Autism can be diagnosed by the history and examination of the child. Assessment tools which evaluate different areas of development that are affected in autism can confirm, and also give information about, the severity of the condition. All children must undergo evaluation for hearing and vision. MRI brain, EEG and genetic testing may be ordered in certain cases.

No single person can manage autism.A Pediatric Neurologist, Developmental Pediatrician, Clinical psychologist and a team of therapists (occupational therapists, behaviour therapists, speech therapist) must work as team for best results. There is as yet no proven role of drugs and nutraceuticals, or stem cell therapy.

Dr. (Col) Rekha Mittal , Additional Director - Pediatric Neurology

Madhukar Rainbow Childrens Hospital, New Delhi

All parents should beaware that autism has been declared as a disability in the Rights of Persons with Disabilites Act of 2016. This entitles the child to a disability certificate or a UDID card. Parents can also avail of Income Tax rebate on expenses occurred in management under Section 80 DD. The Government Insurance scheme , Niramaya can cover some cost of treatment as well, as none of the Insurance companies cover children with autism.

Most of the children are able to attend schools with other children, as awareness and empathy increases amongst the public, and more and more schools are gearing up to educate children with special needs. All in all, children with autism can succeed in school and in life, with the help of doctors and therapists.

This article is part of sponsored content programme.

Read more:
CHILDREN WITH AUTISM: SPECIAL, BUT JUST ONE OF US - The Hindu

Surgery gives teen opportunity to help other kids with cancer – Houston Chronicle

This is a carousel. Use Next and Previous buttons to navigate

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, is an internationally recognized surgeon who focuses on limb salvage at MD Anderson on Tuesday, March 29, 2022 in Houston.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

A bead chain made by Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Hallie Barnard, a 12-year old osteosarcoma survivor who has not only persevered through a cancer diagnosis, but she also was born with a rare anemia condition that required a bone marrow transplant. Photographed at MD Anderson on Tuesday, March 29, 2022 in Houston. Barnard is also a patient of Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, an internationally recognized surgeon who focuses on limb salvage.

Dr. Valerae O. Lewis, chair of orthopaedic oncology at MD Anderson, is an internationally recognized surgeon who focuses on limb salvage at MD Anderson on Tuesday, March 29, 2022 in Houston.

For every procedure Hallie Barnard has undergone at MD Anderson, she receives a bead. The yellow ones symbolize each night in the hospital. The ones that glow in the dark represent radiology appointments.

Theyre for every poke, every wound cleaning, every physical therapy appointment, the 13-year-old said.

MD Anderson launched its Beads of Courage program in 2008 so young patients could document their journeys through cancer treatment. Collecting colorful strings of beads also provides some incentive to show up at dreaded doctor appointments.

Hallie has more than 350 feet of beads.

They symbolize everything that Ive gone through in the past four years, the Denton resident said.

Still, Hallie is less concerned about her own struggles through osteosarcoma, a cancer that begins in the bones, than she is with shining a light on the challenges other children face.

Every time I show people my beads, it dawns on them that children are going through so much, she said. And there are children with longer beads than I have.

According to the American Childhood Cancer Organization, about 15,780 children are diagnosed with cancer in the U.S. each year.

Their studies indicate 1 in 285 children will be diagnosed with cancer before their 20th birthday and that cancer is the leading cause of death for children between the ages of 4 and 14 in the country.

Children are dying of cancer at astonishing rates, Hallie said.

Regardless, she said, childhood cancer research is underfunded. Less than 4 percent of the federal budget for cancer research is dedicated to its study, according to the Childrens Cancer Research Fund, a national nonprofit.

I dont want any of my friends to die anymore, Hallie said. I want to show them that I am there for them. I am their voice. I can speak for those who cannot speak for themselves.

Hallies Heroes, the nonprofit she started with her parents, Elyse and Jesse Barnard, helps fund childrens cancer research.

But thats not how it began. The organization was founded to inspire individuals to register as bone marrow donors. Because, at the time, Hallie was facing another seemingly insurmountable challenge finding a match for herself.

Hallie was diagnosed with Diamond-Blackfan anemia when she was 13 months old.

Your bone marrow is basically what makes your red blood cells, she said. And with DBA, that fails to happen, Hallie said.

Elyse said her daughter did not seem to be growing normally or hitting milestones at the right time during her first year of life.

Our pediatrician would tell me everything was OK, she said. As a first-time mom, we tend to worry about everything, but I knew that something was wrong.

That fear was validated when Hallie went for her 12-month checkup. A blood test revealed low levels of hemoglobin, and she was admitted to the hospital.

Diagnostics pointed to Diamond-Blackfan anemia but doctors were still skeptical due to the rarity of the disease, Elyse said.

In the end, Hallie had a diagnosis. But treatment options were even more elusive.

Only five to seven babies per million have Diamond-Blackfan anemia, according to St. Judes Research Hospital.

Blood transfusions and steroids can be used to manage symptoms, but both take a toll on the body, Elyse said.

Stem cell transplants offer the only possible cure. The issue is finding a donor.

Theres just a 1 percent chance of finding a match for bone marrow transplants, Hallie said.

Her family began looking and moved from Virginia to Texas, after learning that Dallas had one of the four hospitals in the U.S. specializing in the disorder.

Out of the Barnards search for donors, Hallies Heroes was born.

In the search for her own bone marrow donor, other matches were made. So far, there have been 184 and the organization has inspired more than 8,000 people to join the bone marrow registry.

To its mission, Hallies Heroes added funding for Diamond-Blackfan anemia research and covering medical bills.

Hallie found her own match for a bone marrow transplant when she was 9. The procedure was scheduled the following year, 2018.

She was in the hospital for 60 days, kept in isolation for the duration to protect her fragile immune system, which was wiped out by chemo.

After 100 days, the bone marrow transplant is usually considered fully integrated, Elyse said.

You basically do a happy dance, because you have a new immune system, she said. We thought we were in the clear.

But at 120 days, Hallie had a new symptom.

I started getting horrible pains in my leg, she said. We found a small bump, the size of a mosquito bite.

The growth was right above her left knee. Doctors told her to draw a circle around it to see if it grew.

In a week, it had doubled, Hallie said.

Diagnostics revealed the bump was indeed a tumor.

In March 2019, Hallie was diagnosed with osteosarcoma, a bone cancer that develops most often in children and young adults.

Hallie was presented with a few different choices. She could opt for an amputation or limb salvage surgery to remove diseased bone and replace it with a metal implant or a bone graft, called at allograft, from another person.

We wanted to get a second opinion, Hallie said. Our doctor said, I studied under this amazing woman, Dr. Lewis. Yall should go to MD Anderson.

Dr. Valerae O. Lewis serves as the inaugural chair of orthopedic oncology at the hospital. In fact, she created the Department of Orthopedic Oncology in 2014.

The Barnards made an appointment to see her in mid-April 2019.

Data from MD Anderson shows that between 800 and 900 cases of osteosarcoma are diagnosed annually in the U.S. About half of these are children and teens.

Lewis presented Hallie with three options. You can do an amputation, she began.

Historically, that was the only choice available to remove the tumor completely. But now there are additional options limb-salvaging surgery and rotationplasty, Lewis said.

Limb-salvaging surgery can be performed if the cancer has not metastasized.

Limb-salvage is a great option, because it gives kids the ability to keep their legs, Lewis said. But it does take a toll.

Patients activity levels are restricted and additional operations are needed down the road, probably every 15 to 20 years.

The third option, a rotationplasty, removes the tumor along with the middle part of the leg and the knee. The surgeon then rotates the lower leg 180 degrees before reattaching it to the thigh.

Its like an amputation, but we create a new knee, Lewis said.

Rotationplasty allows patients to be higher functioning. Its easier to walk, Lewis said. You can bike, skate and swim. Everything you need a knee for, you can do.

Hallie chose rotationplasty. Surgery was scheduled for late June 2019, and she had chemo before and after surgery.

She was 11 at the time and had complications while healing, including infections. She needed a wound vacuum for about 11 months. When Hallie finished chemo in 2020 in Fort Worth, her bones had not yet fused.

Then, Dr. Lewis came up with a genius idea, Hallie said.

Lewis inserted a titanium rod into the nonhealing site to help.

Hallie said that Lewis restored her confidence.

Theres a point when a patient gives up. And theres also a point when a doctor gives up. She said that she had not given up on my leg yet, Hallie recalled.

After rotationplasty, a prosthesis is worn, and patients have to relearn how to walk.

Even though the ankle now functions as the knee, it is entirely different from the typical configuration, Lewis said.

The foot fits into the prosthesis, she said. And one needs to remember that it is a functional foot interfacing with the prosthesis.

The toes can provide balance and aid in powering the prosthesis, Lewis added. The plantar surface also allows for bearing weight.

Hallie was at MD Anderson for about seven months, working on both physical and occupational therapy, until she headed back to Denton April 8.

Hallie has progressed nicely and is walking distances without support, Lewis said.

With further physical therapy and continued dedication she anticipates Hallie will be running, skipping and jumping in the future.

Hallies follow-up appointments at MD Anderson are scheduled every three months.

When Hallie was first diagnosed with osteosarcoma, she remembers telling her mother, God put me back in the hospital to help other children.

Now she advocates for both children with cancer and those with Diamond-Blackfan anemia.

At one point, while Hallie was healing from surgery, Elyse and Jesse went to a wall where donors names are displayed on the ninth floor of MD Anderson.

Every day, her dad and I passed the wall, Elsye said. One day, she wanted to see Hallie added to the names.

After changing the bylaws of the nonprofit, Hallies Heroes pledged $50,000 over five years in support of Lewis research in the area of pediatric sarcoma.

Hallie went on the wall in November.

It was really cool to come full circle with that, Elyse said. We were once there as parents, not knowing if our child would survive and seeing all the people donate money so that she could.

Now were giving back, because we want other children to survive, she added.

The funding will make a significant impact, Lewis said, and will go toward researching treatments for pediatric sarcoma.

Hallie is a success story, Lewis said. She is our ambassador and is a cheerleader to other patients. She wants to give back and help other kids like her.

Peyton is a Houston-based freelance writer.

Read more:
Surgery gives teen opportunity to help other kids with cancer - Houston Chronicle

Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market – BioSpace

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global regenerative medicine market for the historical period 20172018 and forecast period 20212028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period

Rise in Prevalence of Chronic Diseases, Genetic Disorders, and Cancer: Key Driver

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=419

Key Players Increased Investment in Research & Development of Regenerative Medicine

Get COVID-19 Analysis on Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=419

Costly Treatment Associated with Regenerative Medicine

Make an Enquiry before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=419

Regenerative Medicine Market: Competition Landscape

More Trending Reports by Transparency Market Research

Dermal Fillers Market: https://www.transparencymarketresearch.com/dermal-fillers-market.html

Vascular Injury Treatment Market: https://www.transparencymarketresearch.com/vascular-injury-treatment-market.html

Hepatorenal Syndrome Treatment Market: https://www.transparencymarketresearch.com/hepatorenal-syndrome-treatment-market.html

Surgical Glue Market: https://www.transparencymarketresearch.com/surgical-glue-market.html

Ultrasound Gels Market: https://www.transparencymarketresearch.com/ultrasound-gel-market.html

Diabetic Foot Ulcers Treatment Market: https://www.transparencymarketresearch.com/diabetic-foot-ulcers-treatment-market.html

Menopausal Hot Flashes Market: https://www.transparencymarketresearch.com/menopausal-hot-flashes.html

Orthobiologics Market: https://www.transparencymarketresearch.com/orthobiologics-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

View post:
Regenerative Medicine Market to Reach US$ 12.9 Bn by 2028, Increase in Demand for Customized Regenerative Medicine to Drive the Market - BioSpace

New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital – The…

Amrita Hospitals announced on Thursday that its new 2,400-bed campus will soon be open to the public in Faridabad in August this year. During the press conference on Thursday, hospital management announced that the new Amrita Hospital is spread across 133 acres of land in Faridabad and it will be the biggest private sector hospital in India.

This would be the second large-scale Amrita Hospital in India after the iconic 1,200-bed Amrita Hospital in Kochi, Kerala, which was established 25 years ago by the Mata Amritanandamayi Math.

The new hospital is located at Sector 88, Faridabad and it will have a total built-up area of 1 crore sq. ft., including a 14-floor-high tower that will encompass the key medical facilities and patient areas. During the press conference, Swami Nijamritananda Puri, Head, Mata Amritanandamayi Math, Delhi announced that the 81 specialties at the hospital will include eight centers of excellence, such as oncology, cardiac sciences, neurosciences, gastro-sciences, renal sciences, bone diseases and trauma, transplants, and mother and child.

Radiation exposure in the digital era crushing fertility among men

Cancer vanishes from every patients body in drug trial miraculously; Shocked doctors say First time in history

Ramsay Hunt Syndrome: Know the causes, symptoms and treatment

Sharp Sight Eye Hospitals in collaboration with LOGY.AI introduces Indias first AI-based cataract screening solution

The hospital will become operational in stages, with 500 beds opening in August this year. In two years, this number will rise to 750 beds, and further to 1,000 beds in five years. When fully operational, the hospital will have a staff of 10,000 people, including over 800 doctors.

On how the new hospital has incorporated the aspects of pandemic-induced demands, Dr. Sanjeev K Singh, Medical Director, Amrita Hospital, Faridabad told Financial Express.com: We have learned a lot from the pandemic. The construction of the hospital began 5-6 years ago and the learnings from the pandemic also got incorporated along the way. For example, any patient who comes in an emergency gets facilitated in a 40-bed setup. In that set-up, we have a decontaminated area in which anyone who needs to shower will be sent there. We have four negative pressure rooms and if we have any suspected cases of covid or covid-like diseases we can send them to concerned specialists. The mechanism of shifting is also planned and implemented. In all critical care units, there are positive pressure isolation rooms.

The massive facility will also include 534 critical care beds which is the highest in India, the hospital management claims. The hospital campus will also include 64 modular operation theaters, most advanced imaging services, fully automated robotic laboratory, high-precision radiation oncology, most updated nuclear medicine, and state-of-the-art 9 cardiac and interventional cath lab for clinical services. Cutting-edge medical research will be a strong thrust area, with a dedicated research block spread across a 7-floor building totaling 3 lakh sq. ft with exclusive Grade A to D GMP lab with focus on identifying newer diagnostic markers, AI, ML, Bioinformatics etc.

Dr. Singh also told Financial Express.com that they want to integrate all aspects of medical science and bridge the gap between clinicians and scientists.

In Kochi, we have established tissue engineering, a nano-medicine-based cardiac stent, bone growth, and lots more. What we are looking at Faridabad campus is developing something new in stem-cell therapies. We want to create techniques like creating human cells on our own in our GMP labs as generally, we rely on international counterparts for such procedures. Recently, we conducted research in which we found that we can use patient pluripetin stem cells in tumours and it will destroy them. For us, oncology is the big thrust area but other areas will be a focus too. The intent of our research facility will be to make the high-end expensive equipment and treatments cost-effective for the common man. We want to integrate medicine, engineering, biotechnology, and other segments altogether, Dr. Singh told Financial Express.com.

Dr. Singh also said that they have already been awarded the Advanced ICMR Clinical Trial Unit and this will enable them to conduct their trials in the new facility.

Mata Amritanandamayi has allocated a certain amount of seed money to initiate research. On the basis of submitted proposals, things will materialise and start, he added.

Dr. Singh also told Financial Express.com that the new hospital will also be empaneled. There is a process of 3-6 months and then after medical facilities will be available under all panels like ECHS, CGHS and other TPAs, he added.

During the press conference, Dr Singh also informed that the hospital will be among the very few facilities in the country to conduct hand transplants, a specialty pioneered by Amrita Hospital in Kochi. We will also do transplants of liver, kidney, trachea, vocal cords, intestine, heart, lung, pancreas, skin, bone, face and bone marrow, he said.

Training of medical students and doctors will be a strong focus area. The hospital will have state-of-the-art robotics, haptic, surgical-medical simulation centre spread across 4 floors and 1.5 lakh sq. ft area, the biggest such learning & development facility for doctors in the country. The facility will also host a medical college and the countrys biggest allied health sciences campus, he stated.

Moreover, the management also informed that ultra-modern Amrita Hospital at Faridabad would be one of Indias largest green-building healthcare projects with a low carbon footprint. It is an end-to-end paperless facility, with zero waste discharge.

There is also a helipad on the campus for swift transport of patients and a 498-room guest house where attendants accompanying the patients can stay, they said.

Original post:
New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The...

New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for University Hospitals Seidman Cancer Center – Newswise

Newswise CLEVELAND - One of Americas top cancer doctors with a national and international reputation for cancer research will lead the new Wesley Center for Immunotherapy at University Hospitals Seidman Cancer Center as well as the Division of Hematology.

Koen van Besien, MD, PhD, comes to UH Seidman Cancer Center from New York-Presbyterian Hospital, where he has been Director of the Stem Cell Transplant Program and an attending physician. He is also a Professor of Medicine at Weill Cornell Medical College in New York City.

Dr. van Besien will lead the Wesley Center for Immunotherapy at UH Seidman Cancer Center, a cellular therapy facility that generates CAR-T, NK cell and other cellular-based therapies. Physician-scientists engage in groundbreaking research and bring new, life-extending immunotherapy treatments to patients.UH experts are creating cells for treatment in just eight days an innovation that allows UH Seidman Cancer Center physicians to deliver life-enhancing therapy more quickly than previously possible.

With an established reputation for clinical research and care, Dr. van Besien has made numerous contributions to the field of cellular therapy and stem cell transplantation. Most recently, he has focused on methods to extend the use of transplantation to more patients in need. His group has recently reported the first successful transplant for a patient with HIV and leukemia using a haplo-cord graft a unique procedure developed by his team. The patient remains free of HIV and leukemia more than four years after transplant.

Dr. van Besien is Editor in Chief of the Journal of Leukemia and Lymphoma and a member of the editorial review boards of the journals Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. His NIH-supported research has been published in more than 300 peer-reviewed papers.

Dr. van Besien completed medical school and clinical training at College ND de la Paix in Namur and the University of Leuven, both in Belgium. He holds a PhD from the University of Maastricht in the Netherlands. He completed his hematology/oncology fellowship at Indiana University and in Bruges, Belgium. Dr. van Besien has served on the faculty of MD Anderson Cancer Center in Houston. He also directed transplant programs at the University of Illinois for four years and at the University of Chicago for a decade.

He is fluent in five languages: English, Dutch, German, Spanish and French.

Dr. van Besien joins UH Seidman Cancer Center on July 15.

###

About University Hospitals Seidman Cancer Center/Cleveland, Ohio

UH Seidman Cancer Center is the only freestanding cancer hospital in Northeast Ohio, where all clinicians and staff are dedicated to the prevention, diagnosis and treatment of cancer while researching new and innovative treatment options through clinical trials. Nationally ranked cancer care is also available to patients through the 11-county region at 16 community-based locations. Our UH Seidman specialists make up 14 cancer-specific teams focused on determining integrated care plans tailored to patients needs. UH Seidman Cancer Center is part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, one of 52 comprehensive cancer centers in the country. Patients have access to advanced treatment options, ranging from a pioneering stem cell transplant program founded more than 40 years ago and a wide range of immunotherapy to the first and only proton therapy center in northern Ohio for adults and children. Go to UHhospitals.org/Seidman for more information.

About University Hospitals / Cleveland, Ohio Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 23 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio.The systems flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University and the Technion Israel Institute of Technology. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top childrens hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including Americas Best Hospitals from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH isone of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visitUHhospitals.org.

Here is the original post:
New Hematology Chief and Director of the Wesley Center for Immunotherapy Named for University Hospitals Seidman Cancer Center - Newswise

SummaForte(TM) Adds Two World-Class Leaders in Sports Medicine and Physical Therapy to Advisory Team – Yahoo Finance

Bloomington, Indiana--(Newsfile Corp. - May 25, 2022) - SummaForte has added two respected experts in sports medicine and physical therapy to its team of industry-leading advisors.

Dr. Kevin E. Elder joins SummaForte as a highly regarded sports medicine specialist and sought-after consultant in Tampa, Florida. Dr. Elder spent five years as team physician for the NFL's Tampa Bay Buccaneers. Currently, he's a team physician for the U.S. Soccer and U.S. Ski teams, serves as an assistant team physician for University of South Florida (USF) Athletics, and is a sports medicine consultant for the Tampa Bay Rowdies (USL), the Tampa Bay Rays (MLB), and Tampa Bay Lightning (NHL).

Dr. Elder has more than 23 years' experience in musculoskeletal ultrasound and regenerative medicine and is one of the most experienced practitioners of platelet-rich plasma (PRP) and stem cell treatments in the U.S. He is affiliated with BayCare Medical Group, Tampa Bay's leading multi-specialty group, and is an Associate Clinical Professor at the University of South Florida and Florida State University.

Dr. Kevin Elder working with the Tampa Bay Buccaneers

To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/8328/125264_img1.jpg

"I strive to provide my patients with a higher quality of life while avoiding the toxicities of medications," said Dr. Elder. "I'm always looking for creative solutions for injuries and pain and am excited about the potential for athletes - from professionals to weekend warriors - to benefit from SummaForte's topical kinesiology tape infused with premium CBD and its all-natural CBD drink mix to aid recovery and focus."

Dr. Jeremy Maddox is a physical therapist with more than 20 years' experience working with some of the highest-level athletes in the world, including serving as team physical therapist for the New York Yankees the past 14 seasons.

Dr. Maddox's business philosophy is to provide exceptional evidence-based care, that goes above the expectations of his patients to create a total environment of support, healing, and expertise.

Story continues

He is certified in manual therapy and strength and conditioning and is the owner of Optimal Performance and Physical Therapies, which has become the largest therapist-owned Outpatient Physical Therapy provider in Central Florida and was named "Tampa Bay's Top Workplace" the past 5 years, and "Best of the Bay" in Physical Therapy in 2021.

Dr. Jeremy Maddox

To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/8328/125264_img2.jpg

"I am always looking for new tools to help my patients," said Dr. Maddox. "Summaforte and its premium CBD products offer an opportunity to speed recovery and improve performance that I'm excited to see the medical community embrace. The future of CBD is bright, and I look forward to seeing what continued research reveals about its capabilities to help in the care and betterment of my patients."

Dr. Elder and Dr. Maddox join other leading doctors and rehab therapists advising SummaForte. These experts include Dr. Peter Grinspoon, an Instructor at Harvard Medical School, a primary care physician at Massachusetts General Hospital, and a certified Health and Wellness coach.

Another advisor is Dr. Thomas Klein, a founding member of Commonwealth Orthopedics, which merged into OrthoVirginia, the state's largest provider of advanced orthopedic care and physical therapy. Dr. Klein's expertise includes sports injuries and prevention.

Dr. Lindsey Migliore, a licensed medical doctor in the field of physical medicine and rehabilitation, joined the Advisory Committee last year. She is co-author of The Handbook on Esports Medicine and is at the forefront of addressing health issues in the rapidly expanding esports space. Prestigious recognition for Dr. Andrea Holmes, PhD, one of the founding members of SummaForte's Advisory Committee, includes receiving a Presidential Citation for her leadership in cannabinoid research.

"I'm thrilled and honored to add Kevin and Jeremy to our incredible team of diverse and exceptional advisors," said Jeff Thinnes, CEO and Founder of SummaForte. "They bring the type of experience and creative thinking that has helped thousands of athletes perform at their best. Their insights and counsel will help SummaForte continue to combine the health benefits of CBD with innovative delivery technologies that facilitate recovery and performance."

SummaForte is a new performance and recovery brand that uses CBD and innovative technologies to develop bespoke, science-driven products that enable peak performance, faster recovery, and a healthy lifestyle. SummaForte launched with two signature products:

SummaTape- a lightweight and stretchable cotton-spandex tape that supports muscles and ligaments while enhancing dexterity and facilitating faster recovery. The kinesiology tape is infused with CBD and menthol, delivering a cooling effect while helping reduce inflammation.

SummaMix- An all-natural drink mix featuring a trifecta of healthy nutrients that provide sustained energy (CBD), vision health (lutein) and cognitive acuity (spearmint-based nootropics). Manufactured using a patented DehydraTECH process from Lexaria Biosciences, SummaMix is an effective nutrient carrier that ensures faster onset and higher bio-absorption for stronger efficacy.

This month, SummaForte will launch SummaRest, another all-natural product without melatonin that facilitates fast, sound, restorative sleep.

Contact: Russell Newell Russell.newell@summaforte.com https://summaforte.com https://www.facebook.com/SummaForte https://www.instagram.com/summaforte/ https://twitter.com/SummaForte

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125264

Visit link:
SummaForte(TM) Adds Two World-Class Leaders in Sports Medicine and Physical Therapy to Advisory Team - Yahoo Finance

Leukemia After COVID-19: Is There a Connection? – Healthline

More than 500 million people have been diagnosed with COVID-19 since late 2019. Most people who develop COVID-19 have mild disease, but theres compelling evidence that people with certain health conditions like leukemia are at elevated risk of severe disease or death.

A 2021 study presented at the 63rd American Society of Hematology Annual Meeting and Exposition found that people with blood cancer have a 17 percent chance of dying from COVID-19, significantly higher than the general population.

Its less clear if COVID-19 increases your risk of developing leukemia or other blood cancers. Some researchers think its plausible that COVID-19, in combination with other factors, could contribute to cancer development. At this time, the link remains theoretical.

Read on to learn more about how COVID-19 could, in theory, contribute to the development of leukemia.

Some types of blood cancer have been linked to infections. Its not clear if COVID-19 contributes to the development of leukemia, but scientists have found some theoretical links.

Cancer development is usually a consequence of multiple factors that drive genetic mutations in cancer cells. Its plausible that COVID-19 could predispose your body to cancer or accelerate cancer progression.

Most people with COVID-19 recover within 2 to 6 weeks, but some people have symptoms that linger for months. Its thought that the lingering effects result from chronic low grade inflammation triggered by the SARS-CoV-2 virus that causes COVID-19.

Chronic inflammation can cause DNA damage that contributes to the development of cancer. In a study published in April 2021, researchers hypothesized lingering inflammation in people with COVID-19 could increase cancer risk.

The immune response in people with COVID-19 is orchestrated by pro-inflammatory molecules linked to the development of tumors, specifically:

COVID-19 is also associated with other processes known to drive cancer formation such as:

A few case studies have reported people admitted to the hospital with leukemia shortly after developing COVID-19. However, its not clear if COVID-19 played a role or how much of a role it played. Leukemia may have developed coincidentally.

The authors of a 2022 study present a theoretical framework of how COVID-19 could influence the development of blood cancers. According to the researchers, an abnormal immune response to viral infections can indirectly trigger gene mutations that promote leukemia.

The virus that causes COVID-19 can also significantly interact with the renin-angiotensin system, which is suggested to have a role in the development of cancerous blood cells.

In a case study published in 2021, researchers present the case of a 61-year-old man who developed acute myeloid leukemia 40 days after developing COVID-19. The researchers concluded that more studies are needed to assess whether theres an association between COVID-19 and acute leukemia.

In another case study from 2020, researchers presented a man who developed COVID-19 as the first sign of chronic lymphocytic leukemia (CLL). The researchers found that the persons lymphocyte count doubled over 4 weeks, suggesting the viral infection is associated with the replication of B cells, the type of white blood cell that CLL develops in.

Some other types of viral infections have been linked to the development of leukemia.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and its rates have been increasing. Growing evidence strongly suggests an abnormal immune response to infections early in life is responsible.

Having a human adult T-cell leukemia virus type 1 infection is linked to the development of T-cell leukemia. This virus is transmitted primarily through bodily fluids. The World Health Organization estimates that 5 to 10 million people have the viral infection.

Some types of infections have been linked to the development of another type of blood cancer called lymphoma. They include:

The FDA has approved the drug remdesivir for adults and some children with COVID-19.

At the time of writing, theres no evidence that remdesivir can cause leukemia.

In a 2021 study, a 6-year-old child with newly diagnosed ALL and COVID-19 was treated with remdesivir and convalescent plasma therapy before starting leukemia treatment.

No adverse events were linked to the therapy, and the researchers concluded this treatment could be considered in people with cancer to accelerate the resolution of the viral infection and to start cancer treatment sooner.

Some researchers have raised concerns that the antiviral drug molnupiravir, which received FDA Emergency Use Authorization on December 23, 2021, could potentially cause cancerous mutations or birth defects. Researchers are continuing to examine these potential adverse effects.

The development of blood cancer is complex. Researchers are continuing to examine whether COVID-19 infection can contribute to the development of leukemia or any other blood cancer. Some researchers have posed a theoretical link, but more research is needed.

None of the vaccines approved for use in the United States interact with your DNA or cause cancer, according to the Centers for Disease Control and Prevention (CDC). Its a myth that mRNA vaccines (Pfizer-BioNTech and Moderna) can cause changes to your DNA.

About 25 percent of blood cancer patients dont produce detectable antibodies after vaccination, according to the Leukemia & Lymphoma Society (LLS). However, the CDC continues to recommend that everyone with cancer still get vaccinated.

LLS experts say vaccination should be combined with other prevention precautions for the best protection.

People with cancer seem to be at a higher risk of severe COVID-19. According to the National Cancer Institute, people with blood cancer may have a higher risk of prolonged infection and death than people with solid tumors.

Researchers are continuing to examine the link between leukemia and COVID-19. Strong evidence suggests that people with leukemia are at an increased risk of developing severe COVID-19.

Some researchers have posed that COVID-19 could contribute to leukemia formation, but as of now, the link remains theoretical. Much more research is needed to understand the connection.

Go here to read the rest:
Leukemia After COVID-19: Is There a Connection? - Healthline

Cell Therapy Market Status and Size Report 2030 The Daily Vale – The Daily Vale

Theglobal cell therapy marketsize was valued atUSD 8.1 billion in 2021and is estimated to reachUSD 23.9 billion by 2030, growing at a CAGR of 14.5% over the forecast period. The development of precision medicine and advancements in cellular therapies in context to their efficiency & manufacturing are expected to be major drivers for the market. Moreover, the development of stem cell banking facilities and resultant enhancement of stem cells production, storage, and characterization are also expected to improve the volumetric capabilities of the market at a global level, which is anticipated to directly translate into revenue for this market at a larger level. Ongoing technological advancements in the parent and ancillary markets for stem and non-stem cells usage are expected to reinforce the demand over the forecast period. There are fewer commercialized cellular therapy products in the current market than the number of research products. This is partly due to stringent regulations and the high cost of stem cells.

Cell lines, such as Induced Pluripotent Stem Cells (iPSC) and human Embryonic Stem Cells (hESC) are recognized as having high growth potential; as a result, many research entities and companies are making significant investments in R&D pertaining to iPSC- and hESC-derived products.

Pricing of stem cell transplantation varies from region to region. For instance, the cost of transplantation in the U.S. is higher than that in Germany or China. In March 2018, Alofisel by TiGenix received approval for marketing in Europe. This was the first allogeneic stem cell therapy to be approved in Europe. Furthermore, revenue for certain products varies for the country; for instance, products like INVOSSA received approval for marketing in Korea but have yet to receive marketing authorization in the U.S. Growth is also influenced by the commercialization of unauthorized stem cell treatments revenue generation.

Get PDF for more Professional and Technical insights:https://www.marketstatsville.com/request-sample/cell-therapy-market

Global Cell Therapy Market Definition

Therapy in which viable cells are injected, grafted, or implanted into a patient to effectuate a medicinal effect is known ascell therapy; for instance, In immunotherapy, T-cells capable of fighting cancer cells via cell-mediated immunity are transplanted, and stem cells are grafted to regenerate diseased tissues.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and their clinical translation. Rapid advances in stem cell research have the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. Several unknown therapies are in clinical development.

Furthermore, government and private funding agencies are constantly offering grants to support projects at various stages of clinical trials, increasing the number of ongoing clinical trials.

Research on human embryonic stem cells is ethically controversial. Harvesting embryonic stem cells involves the destruction of human embryos, raising a moral concern. In addition, stringent regulations for obtaining Intellectual Property Rights (IPR) for products or materials used in research are major restraints for commercializing these services. Ethical approval should be obtained to store cell lines and tissues in biorepositories to avoid the usage of tissue for illegal purposes or to identify proxy diseases to claim insurance. Moreover, controversies surrounding the use of embryonic stem cells for research impede the market growth in several regions

You Can Purchase Complete[emailprotected]https://www.marketstatsville.com/buy-now/cell-therapy-market?opt=2950

The study categorizes the cell therapy market based on use type and therapy type at the regional and global levels.

The analysis of the cell therapy market is based on the use of stem cells for clinical and research purposes. The research-use segment dominated the market for the global cell therapy market and accounted for the largest revenue share of 58.3% in 2021. Currently, cell therapies (stem & non-stem cells) are majorly being used for research projects, which in turn, has led to a large revenue share of this segment in 2021. Cell-based therapies are all possibilities for the replacement, repair, restoration, and regeneration of damaged tissues, cells, and organs. As an alternative to traditional treatment strategies, researchers are investing heavily in developing effective and safe cell-based treatments.

Access full Report Description,TOC, Table of Figure, Chart, etc.@https://www.marketstatsville.com/table-of-content/cell-therapy-market

As per the CGT Catapult database of clinical trials, 59 cell and gene therapy trials are ongoing in the UK. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and CD133+ stem cells, mesenchymal stem/stromal cells are some predominantly employed cell types for clinical investigation. Neural cells, bone marrow mononuclear cells, fibroblasts, cornea cells, antigen-presenting cells, epithelial cells, and chondrocytes are some other cells that are being explored for the development of cell therapies.

Asia Pacificaccounts for the highestCAGR during the forecast period

Based on the regions, the global cell therapy market has been segmented across North America, AsiaPacific, Europe, South America, and the Middle East & Africa.In the Asia Pacific, the market for cell therapy is anticipated to witness a lucrative growth rate of 15.5% over the forecast period. Advancements in stem cell therapy in Asian countries are observed to be better than those in the U.S. This has resulted in Asia leading stem cell research. Several stem cell consortiums in Asian countries aim to ensure coordinated and focused R&D programs. Moreover, patients from western countries migrate to Asian countries for treatment, owing to the flexible legal framework.

Companies from Japan, South Korea, India, China, Taiwan, Singapore, and the rest of Asia were active participants in the conference. In addition, the large regional population and untapped potential present in the region have resulted in global firms entering the market. Moreover, this region offers relatively inexpensive manufacturing & operating units for conducting research. These factors are expected to play a major role in expanding the stem cell market in this region.

Request For Report Description @https://www.marketstatsville.com/cell-therapy-market

The cell therapy market is mildly concentrated in nature with few numbers of global players operating in the market such as Kolon TissueGene, Inc., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., Castle Creek Biosciences, Inc., MEDIPOST, Osiris Therapeutics, Inc., PHARMICELL Co., Ltd, Tameika Cell Technologies, Inc., Cells for Cells, NuVasive, Inc., Vericel Corporation, and Celgene Corporation

Continue reading here:
Cell Therapy Market Status and Size Report 2030 The Daily Vale - The Daily Vale